Bladder Cancer
Key Points
- Bladder cancer is the most common malignancy of the urinary system.
- Disease is staged as non-muscle invasive, muscle-invasive, or metastatic.
- Typical early cue is hematuria, with possible frequency, urgency, dysuria, and nocturia.
- Diagnostic pathway starts with cystoscopy and biopsy; TURBT supports both removal and staging.
- Management ranges from bladder-preserving intravesical therapy to radical cystectomy with urinary diversion.
Pathophysiology
Bladder cancer usually begins in the urothelial lining. As tumor invasion depth increases, treatment intensity and prognosis change substantially.
Non-muscle invasive disease may remain localized to superficial bladder layers, while muscle-invasive disease penetrates deeper tissue and carries higher progression risk. Metastatic disease reflects spread beyond the bladder and requires systemic treatment strategies.
Classification
- Non-muscle invasive bladder cancer: Confined to mucosa/submucosa; often managed with local resection and intravesical therapy.
- Muscle-invasive bladder cancer: Invades detrusor muscle; commonly treated with radical cystectomy pathways.
- Metastatic bladder cancer: Spread outside the bladder; systemic therapy focus.
- Screening-evidence context: Routine population screening has not shown mortality benefit, so evaluation is symptom- and risk-driven rather than universal.
Nursing Assessment
NCLEX Focus
Hematuria with irritative voiding symptoms requires prompt malignancy workup rather than watchful symptom treatment alone.
- Assess urinary cues: visible or microscopic hematuria, frequency, urgency, dysuria, and nocturia.
- Review diagnostic trajectory: cystoscopy findings, biopsy confirmation, TURBT results, and staging imaging (CT/MRI/PET).
- Assess treatment impact on elimination pattern and diversion readiness when cystectomy is planned.
- Assess symptom burden and quality-of-life concerns related to voiding changes and cancer diagnosis.
- Assess emotional distress, altered body image/intimacy concerns (especially with ostomy/diversion), and caregiver coping needs.
Nursing Interventions
- Coordinate timely pre/post diagnostic care for cystoscopy, biopsy, and TURBT.
- Reinforce treatment-plan understanding by stage (local intravesical approaches versus radical surgery versus systemic therapy).
- Prepare clients for urinary diversion education when cystectomy is anticipated.
- Support symptom management, surveillance for treatment adverse effects, and timely escalation of worsening urinary findings.
- Reinforce infection-sign education for clients receiving chemotherapy or surgical treatment and escalate concerning symptoms promptly.
- Coordinate psychosocial referrals (nurse specialist, social work/case management, support groups) when coping burden is high.
- Encourage evidence-based coping supports (active listening, relaxation/mindfulness practice) and screen for anxiety/depression.
- Offer palliative-care consultation when symptom burden is high and initiate advance-care-planning discussions as appropriate.
Post-Cystectomy Elimination Transition
After radical cystectomy, urinary flow must be redirected; nurses must prioritize diversion education, monitoring, and complication prevention.
Pharmacology
| Drug Class | Examples | Key Nursing Considerations |
|---|---|---|
| chemotherapy | intravesical/systemic context | Intravesical therapy is common after TURBT in non-muscle invasive disease. |
| immunotherapy | class-based agents | Used in selected advanced pathways; monitor immune-related adverse effects. |
| targeted-therapy | class-based agents | Used for metastatic disease based on tumor profile and treatment response goals. |
Clinical Judgment Application
Clinical Scenario
A client presents with recurrent painless hematuria and urinary urgency. Cystoscopy finds a bladder lesion, and TURBT is scheduled for removal and staging.
- Recognize Cues: Hematuria plus irritative urinary symptoms with cystoscopic lesion.
- Analyze Cues: Findings are consistent with likely urothelial malignancy requiring staging-directed treatment.
- Prioritize Hypotheses: Immediate priorities are diagnostic completion and early treatment coordination.
- Generate Solutions: Prepare for TURBT, reinforce education, and plan post-procedure follow-up.
- Take Action: Implement peri-procedural care and communicate new pathology/staging data promptly.
- Evaluate Outcomes: Stage-appropriate treatment is initiated and urinary symptoms are monitored for response.
Related Concepts
- prostate-cancer - Common co-discussed urinary-system malignancy with different staging and treatment pathways.
- bladder-assessment - Hematuria and voiding-pattern analysis guide escalation.
- postvoid-residual-measurement-and-retention-management - Useful when obstruction or retention develops during disease/treatment.
- benign-prostatic-hyperplasia - Important differential for lower urinary tract symptoms in older adults.
- palliative-care - Supports symptom burden, quality of life, and goals-of-care planning in advanced disease.
Self-Check
- Which finding makes urgent bladder-cancer workup a priority in an older adult with urinary symptoms?
- How does treatment differ between non-muscle invasive and muscle-invasive bladder cancer?
- Why is early urinary-diversion education critical before radical cystectomy?